Halozyme Therapeutics came out with a quarterly loss of $0.01 per share versus Wall Street's estimate of a loss of $0.02. This compares to earnings of $0.85 per share a year ago. This quarterly report represents an earnings surprise of 50%. Last quarter, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.19. Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Halozyme posted revenue of $60.23 million for the quarter ended December 2018. "We have a broad enhanced pipeline with our partners," said Helen Torley, CEO of Halozyme in a conference call. "By the end of 2019, we project this will include three products in Phase 3 clinical testing and nine products in Phase 1 clinical testing. With those key takeaways, let me provide some additional details on our recent progress and results. Earlier this month, we announced a new collaboration with argenx, a development-stage biotechnology company with a focus on severe autoimmune diseases and other therapeutic areas."